![](https://i0.wp.com/brand.education/wp-content/uploads/2019/07/Lupin-Brand-News.jpg?fit=770%2C433&ssl=1)
Lupin aims to launch new products across geographies
Drug maker Lupin is all set to launch its first biosimilar product and commercialize its first inhalation product in the US in the current fiscal.
Addressing shareholders in the company’s Annual Report for 2018-19, Lupin Chief Executive Officer Vinita Gupta and Managing Director Nilesh Gupta said the new launches across the globe would help it achieve sustainable growth.
“Looking ahead, FY2020 is an exciting year for Lupin as we plan to bring our first biosimilar to market, commercialise our first inhalation product in the US, continue the growth momentum in our US generics business and launch our injectables portfolio,” they said in a joint letter to the shareholders.